Search

Your search keyword '"Álvarez-Larrán A"' showing total 9 results
Start Over Author "Álvarez-Larrán A" Journal annals of hematology
9 results on '"Álvarez-Larrán A"'

1. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

Author

Ortuzar, Ariana, Fox, María Laura, Vera, Juan Antonio, Lorenzo Vizcaya, Álvaro, Marín Sánchez, Alberto, Llopis Calatayud, Inmaculada, Carbonell, Sara, Álvarez-Larrán, Alberto, Mata Serna, Raquel, Marco Buades, Josefa E., Quiroz Cervantes, Keina, Martínez Hellín, Ángela, Blum Domínguez, Alejandra, Caballero Navarro, Gonzalo, Cáceres Sansaloni, Amparo, Guerrero Fernández, Lucía, Muñoz Linares, Cristina, Gasior Kabat, Mercedes, Pérez López, Raúl, Fernández Rodríguez, Ángeles, Martínez Bilbao, Cristina, Cobo Rodríguez, María Teresa, Díaz, Álvaro, Durán, M. Antonia, Santaliestra Tomas, Marta, García-Gutierrez, Valentín, Magro Mazo, Elena, Hernández-Boluda, Juan Carlos, Segura, Adrián, Raya, José María, Navas Elorza, Begoña, and Osorio, Santiago

Published
2023
Full Text
View/download PDF

2. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

Author

Triguero, Ana, Pedraza, Alexandra, Pérez-Encinas, Manuel, Mata-Vázquez, María Isabel, Vélez, Patricia, Fox, Laura, Gómez-Calafat, Montse, García-Delgado, Regina, Gasior, Mercedes, Ferrer-Marín, Francisca, García-Gutiérrez, Valentín, Angona, Anna, Gómez-Casares, María Teresa, Cuevas, Beatriz, Martínez, Clara, Pérez, Raúl, Raya, José María, Guerrero, Lucía, Murillo, Ilda, Bellosillo, Beatriz, Hernández-Boluda, Juan Carlos, Sanz, Cristina, and Álvarez-Larrán, Alberto

Published
2022
Full Text
View/download PDF

4. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

Author

Ariana Ortuzar, María Laura Fox, Juan Antonio Vera, Álvaro Lorenzo Vizcaya, Alberto Marín Sánchez, Inmaculada Llopis Calatayud, Sara Carbonell, Alberto Álvarez-Larrán, Raquel Mata Serna, Josefa E. Marco Buades, Keina Quiroz Cervantes, Ángela Martínez Hellín, Alejandra Blum Domínguez, Gonzalo Caballero Navarro, Amparo Cáceres Sansaloni, Lucía Guerrero Fernández, Cristina Muñoz Linares, Mercedes Gasior Kabat, Raúl Pérez López, Ángeles Fernández Rodríguez, Cristina Martínez Bilbao, María Teresa Cobo Rodríguez, Álvaro Díaz, M. Antonia Durán, Marta Santaliestra Tomas, Valentín García-Gutierrez, Elena Magro Mazo, Juan Carlos Hernández-Boluda, Adrián Segura, José María Raya, Begoña Navas Elorza, and Santiago Osorio

Subjects
Myeloproliferative Disorders, SARS-CoV-2, Follow-up, COVID-19, Patient satisfaction, Hematology, General Medicine, Telemedicine, Spain, Primary Myelofibrosis, Ph-MPN, Humans, Pandemics, Polycythemia Vera, Aged, Retrospective Studies, Thrombocythemia, Essential
Abstract

The SARS-CoV-2 pandemic has favored the expansion of telemedicine. Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN) might be good candidates for virtual follow-up. In this study, we aimed to analyze the follow-up of patients with Ph-MPN in Spain during COVID-19, its effectiveness, and acceptance among patients. We present a multicenter retrospective study from 30 centers. Five hundred forty-one patients were included with a median age of 67 years (yr). With a median follow-up of 19 months, 4410 appointments were recorded. The median of visits per patient was 7 and median periodicity was 2.7 months; significantly more visits and a higher frequency of them were registered in myelofibrosis (MF) patients. 60.1% of visits were in-person, 39.5% were by telephone, and 0.3% were videocall visits, with a predominance of telephone visits for essential thrombocythemia (ET) and polycythemia vera (PV) patients over MF, as well as for younger patients ( 50 yr). The proportion of phone visits significantly decreased after the first semester of the pandemic. Pharmacological modifications were performed only in 25.7% of the visits, and, considering overall management, ET patients needed fewer global treatment changes. Telephone contact effectiveness reached 90% and only 5.4% required a complementary in-person appointment. Although 56.2% of the cohort preferred in-person visits, 90.5% of our patients claimed to be satisfied with follow-up during the pandemic, with an 83% of positive comments. In view of our results, telemedicine has proven effective and efficient, and might continue to play a complementary role in Ph-MPN patients' follow-up.

Published
2022

5. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

Author

Ortuzar, Ariana, primary, Fox, María Laura, additional, Vera, Juan Antonio, additional, Lorenzo Vizcaya, Álvaro, additional, Marín Sánchez, Alberto, additional, Llopis Calatayud, Inmaculada, additional, Carbonell, Sara, additional, Álvarez-Larrán, Alberto, additional, Mata Serna, Raquel, additional, Marco Buades, Josefa E., additional, Quiroz Cervantes, Keina, additional, Martínez Hellín, Ángela, additional, Blum Domínguez, Alejandra, additional, Caballero Navarro, Gonzalo, additional, Cáceres Sansaloni, Amparo, additional, Guerrero Fernández, Lucía, additional, Muñoz Linares, Cristina, additional, Gasior Kabat, Mercedes, additional, Pérez López, Raúl, additional, Fernández Rodríguez, Ángeles, additional, Martínez Bilbao, Cristina, additional, Cobo Rodríguez, María Teresa, additional, Díaz, Álvaro, additional, Durán, M. Antonia, additional, Santaliestra Tomas, Marta, additional, García-Gutierrez, Valentín, additional, Magro Mazo, Elena, additional, Hernández-Boluda, Juan Carlos, additional, Segura, Adrián, additional, Raya, José María, additional, Navas Elorza, Begoña, additional, and Osorio, Santiago, additional

Published
2022
Full Text
View/download PDF

8. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.

Author

Senín, Alicia, Fernández-Rodríguez, Concepción, Bellosillo, Beatriz, Camacho, Laura, Longarón, Raquel, Angona, Anna, Besses, Carles, and Álvarez-Larrán, Alberto

Subjects
POLYCYTHEMIA vera, THROMBOCYTOSIS, JANUS kinases, GENETIC mutation, HYDROXYUREA, PATIENTS, ALLELES, AMINO acids, BONE marrow diseases, CYTOGENETICS, GENES, LONGITUDINAL method, PHENYLALANINE, PROTEINS, VALINE, DISEASE progression, NEOPLASTIC cell transformation
Abstract

JAK2V617F monitoring and NGS of non-driver genes was performed in 100 patients with polycythemia vera (PV) or essential thrombocythemia (ET) with long molecular follow-up. Patients who did not progress to myelofibrosis (MF) or acute myeloid leukemia (AML) after more than 10 years (n = 50) showed a low frequency of mutations at first sample (18%) and an incidence rate of 1.7 new mutations × 100 person-years. Mutations were detected at first sample in 83% of PV/ET patients who later progressed to AML (n = 12) with these patients having a rate of 25.6 mutations × 100 person-years. Presence of mutations at diagnosis was the unique risk factor for acquiring a new genetic event (HR 2.7, 95% CI 1.1-6.8, p = 0.03) after correction for age, PV diagnosis, and total duration of hydroxyurea (HU) exposure. Patients with additional mutation at first sample showed a higher probability of developing cytopenia under HU therapy and a higher risk of AML (HR 12.2, 95% CI 2.6-57.1, p = 0.001) with mutations in ASXL1 (p < 0.0001), TP53 (p = 0.01), SRSF2 (p < 0.0001), IDH1/2 (p < 0.0001), and RUNX1 (p < 0.0001) being associated with a higher probability of AML. Myelofibrotic transformation was more frequent in patients with additional mutations, especially in SF3B1 (p = 0.02) and IDH1/2 (p < 0.0001) although a persistently high or a progressive increase of the JAK2V617F allele burden while receiving cytoreduction was the strongest predictor of MF transformation (HR 10.8, 95% CI 2.4-49.1, p = 0.002). In conclusion, NGS may be useful to identify a minority of PV and ET patients with high genetic instability and increased risk of AML transformation. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results